Home
    • Plans Blog Contact
    Neurocrine Biosciences Inc logo

    Neurocrine Biosciences Inc

    NBIX
    Last price US$175.78
    Market cap US$17.8b
    12M price change 33.65%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Neurocrine Biosciences Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Neurocrine Biosciences Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 05, 2026

    Quarterly result summary

    Revenue was $811M (reported); EPS was $197.9 (reported).

    Revenue $811M reported
    EPS $197.9 reported
    Operating income $193.4M +719% YoY
    Net income $197.9M +2405% YoY

    What changed

    • Revenue reported to $811M; EPS reported to $197.9.
    • Operating income +719% YoY to $193.4M.
    • Net income +2405% YoY to $197.9M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 05, 2026 SEC filing 10-Q May 05, 2026 Earnings release Earnings release Feb 11, 2026 SEC filing 8-K Feb 11, 2026 SEC filing 10-K Feb 11, 2026 SEC filing 8-K Oct 28, 2025 Earnings release Earnings release Oct 28, 2025 SEC filing 10-Q Oct 28, 2025 SEC filing 10-Q Jul 30, 2025 SEC filing 8-K Jul 30, 2025 Earnings release Earnings release Jul 30, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    Neurocrine Biosciences Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 3.37/5
    Neurocrine Biosciences Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Neurocrine B... NBIX US$17.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.73/5
    Neurocrine Biosciences Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Neurocrine B... NBIX US$17.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 2.65/5
    Neurocrine Biosciences Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Neurocrine B... NBIX US$17.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Neurocrine Biosciences Inc logo

    Neurocrine Biosciences Inc

    US$175.78

    US$136.81

    -22.2% vs price

    US$17.8b

    2.94%

    33.65%